Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859129 | 0.84 | GABBR2 (0.52) | SRCALDH1A1CYP2C19TSHRSMN1; SMN2 | |
| SCHEMBL2488308 | 0.82 | LMNA (0.50) | SRCALDH1A1CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL7875002 | 0.82 | LMNA (0.50) | SRCALDH1A1CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL5217546 | 0.80 | TAAR1 (0.48) | SRCALDH1A1CYP2C19TAAR1LMNA | |
| SCHEMBL5146431 | 0.80 | SRC (0.44) | SRCALDH1A1CYP2C19TSHRSMN1; SMN2 | |
| SCHEMBL5217923 | 0.80 | TAAR1 (0.48) | SRCALDH1A1CYP2C19TAAR1LMNA | |
| SCHEMBL1003234 | 0.80 | SRC (0.53) | SRCALDH1A1CYP2C19TSHRSMN1; SMN2 | |
| SCHEMBL2486785 | 0.80 | GBA1 (0.49) | SRCALDH1A1CYP2C19GBA1 | |
| SCHEMBL5217555 | 0.80 | TAAR1 (0.48) | SRCALDH1A1CYP2C19TAAR1LMNA | |
| SCHEMBL10638198 | 0.80 | LMNA (0.48) | SRCALDH1A1CYP2C19SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101087754-B | Cyclohexane derivatives | HOFFMANN LA ROCHE | 2012-01-18 | — | — | CN | claimed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | claimed |
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | claimed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | claimed |
| CN-101087754-A | Novel cyclohexane derivatives | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | CN | claimed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | claimed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| CN-105051034-B | azetidinyloxyphenylpyrrolidine compounds | 伊莱利利公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109336865-A | Azetidinyl phenyl pyrrolidine compound | 伊莱利利公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-107001327-A | [(the 3S of crystal (2S) 3,4S) the base of 3 [(1R) 1 ethoxy] 4 (4 methoxyl group 3 { [base of 1 (base of 5 picoline 2) azetidin 3] epoxide } phenyl) 3 crassitude 1] 3 oxopropan, 1,2 glycol | 伊莱利利公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-106795137-A | Azetidinyl phenyl pyrrolidine compound | 伊莱利利公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-101087754-B | Cyclohexane derivatives | HOFFMANN LA ROCHE | 2012-01-18 | — | — | CN | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-4007155-A | SULFONATE | GENERAL ELECTRIC COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | SRC 98/4885ALDH1A1 2621/4885CYP2C19 3273/4885 |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | SULT2A1, PSEN1, PSEN2 | SRC 3461/4885ALDH1A1 427/4885CYP2C19 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.